JW (Cayman) Therapeutics Co Ltd
02126
Company Profile
Business description
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.
Contact
No. 699 Zhong Ke Road
5th Floor, Building B
Pudong New District
Shanghai
CHNT: +86 2150464201
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
281
Stocks News & Analysis
stocks
Oracle shares are up 87% in 2025. Is it a buy?
Oracle’s cloud database business is riding the AI wave.
stocks
Is there a long-term buying opportunity in luxury stocks?
Our analysts think the recent wobble in revenue growth is cyclical, not structural.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,137.80 | 14.90 | 0.16% |
| CAC 40 | 7,872.02 | 41.91 | 0.54% |
| DAX 40 | 23,611.33 | 84.28 | 0.36% |
| Dow JONES (US) | 46,413.28 | 31.74 | 0.07% |
| FTSE 100 | 9,223.32 | 3.36 | -0.04% |
| HKSE | 26,159.12 | 185.02 | -0.70% |
| NASDAQ | 22,701.07 | 87.90 | -0.39% |
| Nikkei 225 | 45,493.66 | 447.85 | 0.99% |
| NZX 50 Index | 13,136.54 | 5.00 | -0.04% |
| S&P 500 | 6,678.58 | 15.17 | -0.23% |
| S&P/ASX 200 | 8,845.90 | 14.30 | 0.16% |
| SSE Composite Index | 3,821.83 | 6.74 | -0.18% |